Kallidinogenase
CAS No.: 9001-01-8 (kinin-releasing activity)

Short Description:

Source: Extracted from porcine pancreas
Function and use:Kallidinogenase is a kind of kallikrein in human tissues and mammals. It exists in the body in the form of an inactive precursor—prekallikrein, which can degrade kininogen into kinin. Kinin can dilate blood vessels and capillaries,increase vascular permeability,improve microcirculation, regulate blood pressure, and reduce myocardial oxygen consumption. This enzyme is also an activating factor, which can activate plasminogen into plasmin, hydrolyze insoluble fibrin into soluble small peptides, thereby leading to thrombolysis, and can also regulate and reduce hypertension. For a variety of heart and cerebrovascular diseases, such as essential hypertension, arteriosclerosis, coronary atherosclerotic heart disease, cerebral arteriosclerosis, cerebral thrombosis, retinal blood supply disorders and peripheral vascular disease.

Kallidinogenase-Pharmacopoeia?Standard:?JP


Product Detail

Product Tags

CAS No.: 9001-01-8
Complies with CP2020,?JP18

Specification

Kallidinogenase

Source

Porcine pancreas

Process description

Kallidinogenase is an enzyme extracted from healthy porcine pancreas, and has kinin-releasing activity based on cleavage of kininogen.

Production

requirements

This product should be extracted from porcine pancreas that has passed quarantine. Production process should conform with the requirements of current version of Good Manufacturing Practice. This product is derived from animals, and appropriate virus inactivation processes should be used for virus safety control during production

Pharmacopoeia standard

CP

JP

for oral

for injection

Character

White or almost white powder. Odorless.

It is freely soluble in water, and practically insoluble in ethanol and diethyl ether.

A white to light brown powder. It is odorless or has a faint, characteristic odor.It is freely soluble in water, and practically insoluble in ethanol (95) and in diethyl ether.

Identification

The value of R should be 0.12~0.17

The value of I does not exceed 0.2

The retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution

the value of R is between 0.12 and 0.16

Test

pH

5.5-7.5

5.5-7.5

Appearance of solution

_______

Should be clear

_______

Purity

≥75%

≥90%

_______

Purity

Fat

The mass of residue is not more than 5mg

The mass of residue is not more than 1mg

Kininase

_______

The value R is not less than 0.8

Trypsin-like substance

_______

The value of T does not exceed 0.05

Protease

A280≤0.2

The value of (A-A0) not more than 0.2

Loss on drying

Not more than 5.0%

Not more than 2.0%

Residue on ignition

Not more than 3.0%

Not more than 3%

Bacterial endotoxin

_______

≤2.5 EU/IU

_______

Kinin-releasing activity

_______

Not less than 500ng bradykinin equivalent/minute/unit

Potency

Activity

_______

Not less than 25IU/mg

Specific activity

≥300IU/mg.pr

≥ 600IU/mg.pr

Not less than 100IU/mg.pr

Microbial limit

TAMC

≤103cfu/g

_______

TYMC

≤102cfu/g

_______

Escherichia coli

Should not be detected per g

_______

Salmonella

Should not be detected per 10g

_______

Storage

Store in an airtight container, protected from

?light of temperature below 20℃

Tight containers

Category

Vasodilators.

Preparation

Kallidinogenase enteric-coated tablets

Indications

It can be used for a variety of cardiac and cerebrovascular lesions, such as essential hypertension, arteriosclerosis, coronary atherosclerotic heart disease, cerebral arteriosclerosis, cerebral thrombosis, retinal blood supply disorders and peripheral vascular lesions. Recent studies have found that this product can be used to prevent diabetic microangiopathy and early diabetic nephropathy (has a good therapeutic effect and can reduce the amount of urine albumin excreted).


  • Previous:
  • Next:

  • Write your message here and send it to us